Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) revealed on Tuesday the completion of the sale of its oral solid, biologics, and sterile product manufacturing and packaging facility in Europe to Catalent Inc for an undisclosed amount.
Based in in Anagni, Italy, the facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines, as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics.
The Anagni facility divestiture is part of Bristol-Myers Squibb's strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline.
In addition, Bristol-Myers Company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal